The nanoparticle-mediated receptor signaling pathway corresponds to the growing role of receptor-targeted nanocarrier systems–including EGFR-, LRP1-, and TfR-mediated transport–in glioma therapy, enabling blood–brain barrier penetration and tumor-specific drug delivery via receptor interactions (García et al., 2025). The gene discussed is TFRC; the disease is central nervous system cancer.